Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of daratumumab + carfilzomib + lenalidomide + dexamethasone versus carfilzomib + lenalidomide + dexamethasone versus bortezomib + lenalidomide + dexamethasone in newly diagnosed multiple myeloma
2019-001645-41Phase 2Active
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of daratumumab, carfilzomib, lenalidomide, dexamethasone and bortezomib in multiple myeloma (MM) (3 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: MRD negativity after eight cycles of therapy. Started Jan 2020; status: active.
02
Drugs
daratumumabcarfilzomiblenalidomidedexamethasonebortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2019-001645-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001645-41.